(1) A hospital licensed or certified pursuant to section 25-1.5-103, a prescription drug outlet located within the hospital that is dispensing a controlled substance for a chart order or dispensing less than or equal to a twenty-four-hour supply of a controlled substance, and an emergency medical service provider certified or licensed pursuant to section 25-3.5-203 are exempt from the reporting provisions of this part 4. A hospital prescription drug outlet licensed pursuant to section 12-280-114 shall comply with the provisions of this part 4 for controlled substances dispensed for outpatient care that have more than a twenty-four-hour supply.
(2) A prescription drug outlet that does not report controlled substance data to the program due to a lack of electronic automation of the outlet's business may apply to the board for a waiver from the reporting requirements.
Source: L. 2019: Entire title R&RE with relocations, (HB 19-1172), ch. 136, p. 1500, � 1, effective October 1; (1) amended, (SB 19-242), ch. 396, p. 3532, � 28, effective October 1.
Editor's note: (1) This section is similar to former � 12-42.5-408 as it existed prior to 2019.
(2) Before its relocation in 2019, this section was amended in SB 19-242. Those amendments were superseded by the repeal and reenactment of this title 12, effective October 1, 2019. For those amendments to the former section in effect from May 31, 2019, to October 1, 2019, see SB 19-242, chapter 396, Session Laws of Colorado 2019.
12-280-409. Examination and analysis of prescription drug monitoring program - recommendations to executive director. (1) The executive director shall create a prescription drug monitoring program task force or consult with and request assistance from the Colorado team assembled by the governor's office to develop a strategic plan to reduce prescription drug misuse, or its successor group, in order to:
(a) Examine issues, opportunities, and weaknesses of the program, including how personal information is secured in the program and whether inclusion of personal identifying information in the program and access to that information is necessary;
(b) Make recommendations to the executive director on ways to make the program a more effective tool for practitioners and pharmacists in order to reduce prescription drug misuse in this state; and
(c) Evaluate and make recommendations to the executive director, after engaging in a stakeholder process, regarding balancing the program as a health-care tool with the enforcement of this article 280.
(2) If the executive director convenes a task force or obtains assistance from the Colorado team, the applicable group shall submit annual reports to the executive director and the general assembly detailing its findings and recommendations. Notwithstanding section 24-1-136 (11), the requirement in this section to report to the general assembly continues indefinitely.
(3) If the executive director convenes a task force, the members of the task force serve on a voluntary basis and are not entitled to compensation or expense reimbursement.
Source: L. 2019: Entire title R&RE with relocations, (HB 19-1172), ch. 136, p. 1501, � 1, effective October 1. L. 2022: (1) amended, (SB 22-027), ch. 265, p. 1934, � 3, effective May 27.
Editor's note: This section is similar to former � 12-42.5-408.5 as it existed prior to 2019.